687631-80-7

Usage

Main Properties

1. Chemical Structure: Consists of a benzene ring with a nitro group (-NO2) and an amino group (-NH2) attached, along with a carboxylic acid group (-COOH) and a methyl ester (-COOCH3).
2. Functional Groups: Contains key functional groups such as nitro, amino, carboxylic acid, and ester.
3. Molecular Formula: Typically represented as C9H9NO5.
4. Molecular Weight: Calculated approximately as 211.17 g/mol.

Specific Content

1. Medicinal and Pharmaceutical Applications:
Building Block: Used as a foundational component in the synthesis of various drugs and pharmaceuticals.
Drug Development: Its chemical structure and properties make it valuable in developing new drugs and therapeutic compounds.
Synthetic Role: Plays a crucial role in the creation of pharmaceuticals with diverse applications.

2. Potential Uses in Chemical Synthesis:
Versatile Reactivity: Its unique structure and reactivity may find applications beyond pharmaceuticals.
Chemical Synthesis: Could be employed in other chemical synthesis processes due to its versatile nature.

3. Overall Significance:
Synthesis and Development: Plays a significant role in the synthesis and development of pharmaceuticals and other chemical compounds.
Industry Impact: Contributes to advancements in the pharmaceutical industry by facilitating the creation of new drugs and therapeutic agents.

ALFA-AMINO-3-NITROBENZENEACTIC ACID METHYL ESTER serves as a fundamental building block in pharmaceutical synthesis, owing to its diverse functional groups and reactivity, potentially impacting various aspects of drug development and chemical synthesis processes.

Upstream product

• 67-56-1 methanol 
• 30077-08-8 d-α-amino-m-nitrophenylacetic acid 
• 15028-39-4 L-2-phenylglycine methyl ester hydrochloride 
• 2835-06-5 phenylglycin 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors

Abstract: Bacterial resistance represents a worldwide emergency threatening the efficacy of all available antibiotics. Among the several resistance mechanisms developed by bacteria, β-lactamase enzymes?(BLs), which are able to inactivate most β-lactam core antibiotics, represent a key target to block, thus prolonging antibiotics half-life. Several approaches aimed at inhibiting β-lactamases have been so far undertaken, mainly involving β-lactam-like or covalent inhibitors. Applying a structure-based de novo design approach, we recently discovered a novel, non-covalent and competitive inhibitor of AmpC β-lactamase:?lead 1. It has a Ki of 1 μM, a ligand efficiency of 0.38 kcal mol?1 and lead-like physical properties. Moreover, it reverts resistance to ceftazidime in bacterial pathogens expressing AmpC and does not up-regulate β-lactamases expression in cell culture. Its features make it a good candidate for chemical optimization: starting from lead 1 crystallographic complex with AmpC, 11 analogs were designed to complement additional AmpC sites, then synthesized and tested against clinically resistant pathogens. While the new inhibitors maintain similar in vitro activity as the starting lead, some of them, in biological assays, extert a higher potency showing improved synergic activity with ceftazidime in resistant clinically isolated strains. Graphical Abstract: [InlineMediaObject not available: see fulltext.].

Ru-catalyzed C[sbnd]H functionalization of phenylglycine derivatives: Synthesis of isoquinoline-1-carboxylates and isoindoline-1-carboxylates

The reaction of N-unprotected methylesters of phenylglycine derivatives (1a–1f) with electron-rich internal alkynes (2a–2e), catalyzed by [Ru(cymene)Cl2]2 (10%), gives the corresponding 3,4-disubstituted isoquinoline-1-carboxylates 3 through C[sbnd]H/N[sbnd]H oxidative coupling. The C[sbnd]H bond activation step is assisted by carboxylates, and N-fluoro-2,4,6-trimethylpyridinium triflate works as the terminal oxidant. The process shows a remarkable tolerance to the presence of diverse electron-releasing and electron-attracting functional groups at the phenyl ring of the amino acid. In addition, the reaction of phenylglycine derivatives (1a–1f) with methyl acrylate (4a) catalyzed by [Ru(cymene)Cl2]2 (10%) under the same experimental conditions, gives the corresponding 3,N-disubstituted isoindoline-1-carboxylates 5 through C[sbnd]H/N[sbnd]H coupling. Isoindolines 5 are obtained as a mixture of diastereoisomers, with moderate to high values of diastereomeric excess (up to 80%).

GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention provides gonadotropin releasing hormone receptor antagonists and the pharmaceutical composition comprising the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease

ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as "APSAP compounds"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.

MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF

Provided are compounds that are modulators of C3a receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, the compounds are pyridones. In certain embodiments, provided are methods for treatment or amelioration of diseases associated with modulation of C3a receptor activity.